About Alan Ezekowitz
Alan Ezekowitz is a board director at AI3 Bio, Inc., which is developing lipid nanoparticle and antibody therapies that target the T cells involved in autoimmune disease.
Earlier in his career, Ezekowitz was president and chief executive officer of Abide Therapeutics, Inc. from 2011 to 2019. He co-founded the company, which developed a treatment for movement and mood disorders before Lundbeck acquired it in 2019. He was senior vice president and franchise head at Merck from 2006 to 2011. From 1995 to 2005, he was the Charles Wilder Professor of Pediatrics at Harvard Medical School. During that time, he also served as chief of pediatric services at Massachusetts General Hospital for Children and Partners HealthCare System. He has served as a director of Fulcrum Therapeutics, Inc. since 2016. He previously served on the Partners HealthCare Board.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Alan Ezekowitz in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Alan Ezekowitz works with at each company, as listed on that company's latest Form D.
